{"preliminary_commentary":{"by_channel":{"youtube":7,"x_thread":6,"podcast":4,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04675827\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"Decrescendo","nct_id":"NCT04675827","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=decrescendo-nct04675827. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Decrescendo","arms":[{"description":"Treatment administration: adjuvant pertuzumab + trastuzumab (P+T) fixed dose combination (FDC) SC for 14 cycles.\n\nSub-study: 121 of the subjects who achieved a pCR (thus assigned to continue treatment with P+T FDC SC) will be randomised at a 1:1 ratio to receive 3 cycles of P+T FDC SC in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period.","label":"RCB = 0","type":"EXPERIMENTAL"},{"description":"Treatment administration:adjuvant T-DM1 for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.","label":"RCB > 0","type":"EXPERIMENTAL"}],"collaborators":["Breast International Group","Hoffmann-La Roche","International Drug Development Institute","Institut Curie"],"completion_date":{"date":"2024-11-26","type":"ACTUAL"},"conditions":["HER2-positive Breast Cancer","ER-Negative Breast Cancer","PR-Negative Breast Cancer","Node-negative Breast Cancer"],"enrollment":{"count":139,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pertuzumab and tratuzumab fixed dose combination","otherNames":["Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles","Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles"],"type":"DRUG"},{"name":"Trastuzumab emtansine","otherNames":["Adjuvant T-DM1"],"type":"DRUG"}],"last_update":"2024-12-04","lead_sponsor":"Jules Bordet Institute","official_title":"De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-11-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"3-year RFS in HER2-enriched subjects who achieve a pCR","timeFrame":"3 years"}],"references":[{"citation":"Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, Foukakis T, Matikas A. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2025 Mar 12;23(4):e247093. doi: 10.6004/jnccn.2024.7093.","pmid":"40073831","type":"DERIVED"}],"start_date":{"date":"2022-01-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","url":"https://clinicaltrials.gov/study/NCT04675827"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/decrescendo-nct04675827"}